Touchlight AAV is advancing gene therapy by offering its synthetic, linear, double stranded DNA as the new industry standard for transfection-based AAV production. We believe it is a safer, more effective, more scalable and faster way to manufacture AAV.
dbDNA is produced enzymatically and eliminates bacterial sequences, thus preventing aberrant packaging of bacterial origins of replication and antibiotic resistance genes. dbDNA is manufactured from milligram to multi-gram scale with an identical process, in the same facility – we can grow with your success.
Brands: Touchlight AAV is advancing gene therapy by offering its synthetic, linear, double stranded DNA as the new industry standard for transfection-based AAV production.